关注
Florian Lordick
Florian Lordick
University Cancer Center Leipzig
在 medizin.uni-leipzig.de 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
The Lancet 376 (9742), 687-697, 2010
79572010
Gastric cancer
EC Smyth, M Nilsson, HI Grabsch, NCT van Grieken, F Lordick
The Lancet 396 (10251), 635-648, 2020
29122020
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with …
M Peeters, TJ Price, A Cervantes, AF Sobrero, M Ducreux, Y Hotko, ...
Journal of clinical oncology 28 (31), 4706-4713, 2010
12562010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
G Folprecht, T Gruenberger, WO Bechstein, HR Raab, F Lordick, ...
The lancet oncology 11 (1), 38-47, 2010
12192010
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F Lordick, C Mariette, K Haustermans, R Obermannová, D Arnold
Annals of Oncology 27, v50-v57, 2016
9942016
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
F Lordick, YK Kang, HC Chung, P Salman, SC Oh, G Bodoky, G Kurteva, ...
The lancet oncology 14 (6), 490-499, 2013
9562013
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
F Lordick, K Ott, BJ Krause, WA Weber, K Becker, HJ Stein, S Lorenzen, ...
The lancet oncology 8 (9), 797-805, 2007
9532007
Oesophageal cancer
EC Smyth, J Lagergren, RC Fitzgerald, F Lordick, MA Shah, P Lagergren, ...
Nature reviews Disease primers 3 (1), 1-21, 2017
8702017
Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer …
C Schuhmacher, S Gretschel, F Lordick, P Reichardt, W Hohenberger, ...
Journal of clinical oncology 28 (35), 5210-5218, 2010
8522010
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
T Kojima, MA Shah, K Muro, E Francois, A Adenis, CH Hsu, T Doi, ...
Journal of Clinical Oncology 38 (35), 4138-4148, 2020
7612020
Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter …
H Yang, H Liu, Y Chen, C Zhu, W Fang, Z Yu, W Mao, J Xiang, Y Han, ...
Journal of Clinical Oncology 36 (27), 2796-2803, 2018
7112018
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment
HA Wieder, BLDM Brucher, F Zimmermann, K Becker, F Lordick, A Beer, ...
Journal of Clinical Oncology 22 (5), 900-908, 2004
5812004
Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction
K Ott, WA Weber, F Lordick, K Becker, R Busch, K Herrmann, H Wieder, ...
Journal of Clinical Oncology 24 (29), 4692-4698, 2006
5662006
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
F Lordick, F Carneiro, S Cascinu, T Fleitas, K Haustermans, G Piessen, ...
Annals of Oncology 33 (10), 1005-1020, 2022
5632022
Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE …
MA Shah, T Kojima, D Hochhauser, P Enzinger, J Raimbourg, ...
JAMA oncology 5 (4), 546-550, 2019
4462019
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic …
MS Aapro, SM Grunberg, GM Manikhas, G Olivares, T Suarez, ...
Annals of oncology 17 (9), 1441-1449, 2006
4462006
Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial
K Ott, U Fink, K Becker, A Stahl, HJ Dittler, R Busch, H Stein, F Lordick, ...
Journal of clinical oncology 21 (24), 4604-4610, 2003
4192003
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer
E Van Cutsem, Y Kang, H Chung, L Shen, A Sawaki, F Lordick, J Hill, ...
J clin oncol 27 (18), LBA4509, 2009
4062009
ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
Lancet 376 (9742), 687-697, 2010
3862010
ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in …
J Hoeppner, F Lordick, T Brunner, T Glatz, P Bronsert, N Röthling, ...
BMC cancer 16, 1-10, 2016
3192016
系统目前无法执行此操作,请稍后再试。
文章 1–20